

Press Release

12 October 2021 08:30:00 CEST

2cureX provides commercial goals for 2022 at Live Strategy Update on the 12th of October 2021.

2cureX AB (publ) will hold a Live Strategy Update session on 12th October at 13:00 (CET). Presentations will be followed by a Questions & Answers discussion moderated by Redeye's Equity Analyst, Erik Nordström.

2cureX's CEO Fernando Andreu, together with Ole Thastrup (CSO), Pia van der Zee (VP of Marketing) and Jesper Floyd Kristiansen (VP of Sales) will present 2cureX's overall strategy based on three pillars: IndiTreat Technology, Product Portfolio and Sales and Marketing. The presentations will highlight the main topics in each of the three areas, as well as the goals to be achieved in 2022. 2cureX is fully focused on the rollout of its first IndiTreat® products in Europe through the expansion of its distributor network. The company plans to be present in 20 European countries by the end of 2022 and have 30 hospitals using IndiTreat®. The company will also unveil plans to launch one additional metastatic colorectal cancer test in December 2021 and one more in 2022. A broad market penetration in terms of number of hospitals is seen as the key factor to drive sales growth.

We encourage present and potential future shareholders to listen to the Strategy Update to receive the latest news and plans going forward.

Link to Strategy Update webcast:

<https://www.redeye.se/events/818830/strategy-update-2curex>

Link to registration:

https://www.lyyti.fi/reg/Strategy_Update_2cureX

The presentation will be held in English.

For more information about 2cureX:

Fernando Andreu, Chief Executive Officer

E-mail: fa@2curex.com

Telephone: +45 2279 5399

www.2curex.com

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first IndiTreat® test is aimed at optimizing treatment decisions in patients with metastatic colorectal cancer facing their third line of therapy. Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related *In Vitro Diagnostic* (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-10-12 08:30 CEST.

Attachments

[2cureX provides commercial goals for 2022 at Live Strategy Update on the 12th of October 2021.](#)